#biotech

#biotech

Teleskope - $25M Series A Teleskope, a data protection and security platform, has raised $25M in Series A funding led by M13. Founded by Elizabeth Nammour and Julie Trias in 2022, Teleskope has now raised a total of $32.2M in reported equity funding. AUI - $20M Venture AUI, the company building neuro-symbolic foundation models for task-oriented conversational AI, has raised $20M in Venture funding from New Era Capital Partners and eGateway Capital.

We're all living in a cyberpunk novel now. Unconstrained billionaires have space programs and robot armies. People are falling in love with and marrying AI chatbots. You can make movies where you're the star by typing a few sentences. Companies offer designer babies as a service. We've got brain implants for controlling computers, flying cars, robotic surgery, AI-controlled prosthetic limbs, and millions of drones in the sky. So why is the most effective form of communication still a hand-written note?

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood ( NASDAQ:HOOD ) and Fidelity. Now, it no longer takes a lot of money to make money on Wall Street, as investors can buy fractional shares with as little as $5 or $10. That opens doors for everyday people to build portfolios without needing thousands upfront. But that doesn't mean buying cheap stocks is always a good idea, since a low price could signal company problems - and certainly steer clear of penny stocks, which carry high risks of fraud and volatility. Sometimes, though, a low share price signals real opportunity.

Despite my husband and my family's belief that our decision to leave the matrix to live on a homestead in the mountains was spontaneous, people don't just wake up one day and realize they don't fit in. That moment of clarity is the culmination of years of being different. After all, in high school, I was voted least likely to conform.

Gameto, a biotech company focused on women's reproductive health using cell engineering, has raised $44M in Series C funding led by Overwater Ventures.

Concentra Biosciences is rapidly acquiring struggling biotech companies, taking advantage of Bay Area firms' difficulties, including its recent purchase of Cargo Therapeutics, which faced severe setbacks this year.

Colossal Biosciences claims to have restored the dire wolf, but in reality, they merely edited gray wolf genes, raising questions about species definition.

The market for these instruments has clearly evaporated due to government funding cuts, pushing Eikon to pause the development of advanced lab tools for researchers.